DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ambien CR (Zolpidem Tartrate) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in other sections of the labeling:

  • Serious anaphylactic and anaphylactoid reactions [see Warnings and Precautions]
  • Abnormal thinking, behavior changes, and complex behaviors [see Warnings and Precautions]
  • Withdrawal effects [see Warnings and Precautions]
  • CNS-depressant effects [see Warnings and Precautions]

Clinical trials experience

Associated with discontinuation of treatment: In 3-week clinical trials in adults and elderly patients (> 65 years), 3.5% (7/201) patients receiving Ambien CR 6.25 or 12.5 mg discontinued treatment due to an adverse reaction as compared to 0.9% (2/216) of patients on placebo. The reaction most commonly associated with discontinuation in patients treated with Ambien CR was somnolence (1%).

In a 6-month study in adult patients (18–64 years of age), 8.5% (57/669) of patients receiving Ambien CR 12.5 mg as compared to 4.6% on placebo (16/349) discontinued treatment due to an adverse reaction. Reactions most commonly associated with discontinuation of Ambien CR included anxiety (anxiety, restlessness or agitation) reported in 1.5% (10/669) of patients as compared to 0.3% (1/349) of patients on placebo, and depression (depression, major depression or depressed mood) reported in 1.5% (10/669) of patients as compared to 0.3% (1/349) of patients on placebo.

Data from a clinical study in which selective serotonin reuptake inhibitor- (SSRI-) treated patients were given zolpidem revealed that four of the seven discontinuations during double-blind treatment with zolpidem (n=95) were associated with impaired concentration, continuing or aggravated depression, and manic reaction; one patient treated with placebo (n =97) was discontinued after an attempted suicide.

Most commonly observed adverse reactions in controlled trials: During treatment with Ambien CR in adults and elderly at daily doses of 12.5 mg and 6.25 mg, respectively, each for three weeks, the most commonly observed adverse reactions associated with the use of Ambien CR were headache, next-day somnolence, and dizziness.

In the 6-month trial evaluating Ambien CR 12.5 mg, the adverse reaction profile was consistent with that reported in short-term trials, except for a higher incidence of anxiety (6.3% for Ambien CR versus 2.6% for placebo).

Adverse reactions observed at an incidence of ≥1% in controlled trials: The following tables enumerate treatment-emergent adverse reaction frequencies that were observed at an incidence equal to 1% or greater among patients with insomnia who received Ambien CR in placebo-controlled trials. Events reported by investigators were classified utilizing the MedDRA dictionary for the purpose of establishing event frequencies. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice, in which patient characteristics and other factors differ from those that prevailed in these clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigators involving related drug products and uses, since each group of drug trials is conducted under a different set of conditions. However, the cited figures provide the physician with a basis for estimating the relative contribution of drug and nondrug factors to the incidence of side effects in the population studied.

The following tables were derived from results of two placebo-controlled efficacy trials involving Ambien CR. These trials involved patients with primary insomnia who were treated for 3 weeks with Ambien CR at doses of 12.5 mg (Table 1) or 6.25 mg (Table 2), respectively. The tables include only adverse reactions occurring at an incidence of at least 1% for Ambien CR patients and with an incidence greater than that seen in the placebo patients.

Table 1. Incidences of Treatment-Emergent Adverse Reactions in a 3-Week Placebo-Controlled Clinical Trial in Adults (percentage of patients reporting)
Body System/Adverse Reaction Reactions reported by at least 1% of patients treated with Ambien CR and at greater frequency than in the placebo group. Ambien CR
12.5 mg
Placebo
(N = 102) (N = 110)
Infections and infestations
Influenza 3 0
Gastroenteritis 1 0
Labyrinthitis 1 0
Metabolism and nutrition disorders
Appetite disorder 1 0
Psychiatric disorders
Hallucinations Hallucinations included hallucinations NOS as well as visual and hypnogogic hallucinations. 4 0
Disorientation 3 2
Anxiety 2 0
Depression 2 0
Psychomotor retardation 2 0
Binge eating 1 0
Depersonalization 1 0
Disinhibition 1 0
Euphoric mood 1 0
Mood swings 1 0
Stress symptoms 1 0
Nervous system disorders
Headache 19 16
Somnolence 15 2
Dizziness 12 5
Memory disorders Memory disorders include: memory impairment, amnesia, anterograde amnesia. 3 0
Balance disorder 2 0
Disturbance in attention 2 0
Hypoesthesia 2 1
Ataxia 1 0
Paresthesia 1 0
Eye disorders
Visual disturbance 3 0
Eye redness 2 0
Vision blurred 2 1
Altered visual depth perception 1 0
Asthenopia 1 0
Ear and labyrinth disorders
Vertigo 2 0
Tinnitus 1 0
Respiratory, thoracic and mediastinal disorders
Throat irritation 1 0
Gastrointestinal disorders
Nausea 7 4
Constipation 2 0
Abdominal discomfort 1 0
Abdominal tenderness 1 0
Frequent bowel movements 1 0
Gastroesophageal reflux
disease
1 0
Vomiting 1 0
Skin and subcutaneous tissue disorders
Rash 1 0
Skin wrinkling 1 0
Urticaria 1 0
Musculoskeletal and connective tissue disorders
Back pain 4 3
Myalgia 4 0
Neck pain 1 0
Reproductive system and breast disorders
Menorrhagia 1 0
General disorders and administration site conditions
Fatigue 3 2
Asthenia 1 0
Chest discomfort 1 0
Investigations
Blood pressure increased 1 0
Body temperature increased 1 0
Injury, poisoning and procedural complications
Contusion 1 0
Social circumstances
Exposure to poisonous plant 1 0
Table 2. Incidences of Treatment-Emergent Adverse Reactions in a 3-Week Placebo-Controlled Clinical Trial in Elderly (percentage of patients reporting)
Body System/Adverse Reaction Reactions reported by at least 1% of patients treated with Ambien CR and at greater frequency than in the placebo group. Ambien CR Placebo
6.25 mg
(N=99)
(N=106)
Infections and infestations
Nasopharyngitis 6 4
Lower respiratory tract infection 1 0
Otitis externa 1 0
Upper respiratory tract infection 1 0
Psychiatric disorders
Anxiety 3 2
Psychomotor retardation 2 0
Apathy 1 0
Depressed mood 1 0
Nervous system disorders
Headache 14 11
Dizziness 8 3
Somnolence 6 5
Burning sensation 1 0
Dizziness postural 1 0
Memory disorders Memory disorders include: memory impairment, amnesia, anterograde amnesia. 1 0
Muscle contractions involuntary 1 0
Paresthesia 1 0
Tremor 1 0
Cardiac disorders
Palpitations 2 0
Respiratory, thoracic and mediastinal disorders
Dry throat 1 0
Gastrointestinal disorders
Flatulence 1 0
Vomiting 1 0
Skin and subcutaneous tissue disorders
Rash 1 0
Urticaria 1 0
Musculoskeletal and connective tissue disorders
Arthralgia 2 0
Muscle cramp 2 1
Neck pain 2 0
Renal and urinary disorders
Dysuria 1 0
Reproductive system and breast disorders
Vulvovaginal dryness 1 0
General disorders and administration site conditions
Influenza like illness 1 0
Pyrexia 1 0
Injury, poisoning and procedural complications
Neck injury 1 0

Dose relationship for adverse reactions: There is evidence from dose comparison trials suggesting a dose relationship for many of the adverse reactions associated with zolpidem use, particularly for certain CNS and gastrointestinal adverse events.

Other adverse reactions observed during the premarketing evaluation of Ambien CR: Other treatment-emergent adverse reactions associated with participation in Ambien CR studies (those reported at frequencies of <1%) were not different in nature or frequency to those seen in studies with immediate-release zolpidem tartrate, which are listed below.

Adverse Events Observed During the Premarketing Evaluation of Immediate-Release Zolpidem Tartrate: Immediate-release zolpidem tartrate was administered to 3,660 subjects in clinical trials throughout the U.S., Canada, and Europe. Treatment-emergent adverse events associated with clinical trial participation were recorded by clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals experiencing treatment-emergent adverse events, similar types of untoward events were grouped into a smaller number of standardized event categories and classified utilizing a modified World Health Organization (WHO) dictionary of preferred terms.

The frequencies presented, therefore, represent the proportions of the 3,660 individuals exposed to zolpidem, at all doses, who experienced an event of the type cited on at least one occasion while receiving zolpidem. All reported treatment-emergent adverse events are included, except those already listed in the table above of adverse events in placebo-controlled studies, those coding terms that are so general as to be uninformative, and those events where a drug cause was remote. It is important to emphasize that, although the events reported did occur during treatment with Ambien, they were not necessarily caused by it.

Adverse events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 subjects; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in less than 1/1,000 patients.

Autonomic nervous system: Frequent: dry mouth. Infrequent: increased sweating, pallor, postural hypotension, syncope. Rare: abnormal accommodation, altered saliva, flushing, glaucoma, hypotension, impotence, increased saliva, tenesmus.

Body as a whole: Frequent: asthenia. Infrequent: chest pain, edema, falling, fever, malaise, trauma. Rare: allergic reaction, allergy aggravated, anaphylactic shock, face edema, hot flashes, increased ESR, pain, restless legs, rigors, tolerance increased, weight decrease.

Cardiovascular system: Infrequent: cerebrovascular disorder, hypertension, tachycardia. Rare: angina pectoris, arrhythmia, arteritis, circulatory failure, extrasystoles, hypertension aggravated, myocardial infarction, phlebitis, pulmonary embolism, pulmonary edema, varicose veins, ventricular tachycardia.

Central and peripheral nervous system: Frequent: ataxia, confusion, drowsiness, drugged feeling, euphoria, insomnia, lethargy, lightheadedness, vertigo. Infrequent: agitation, decreased cognition, detached, difficulty concentrating, dysarthria, emotional lability, hallucination, hypoesthesia, illusion, leg cramps, migraine, nervousness, paresthesia, sleeping (after daytime dosing), speech disorder, stupor, tremor. Rare: abnormal gait, abnormal thinking, aggressive reaction, apathy, appetite increased, decreased libido, delusion, dementia, depersonalization, dysphasia, feeling strange, hypokinesia, hypotonia, hysteria, intoxicated feeling, manic reaction, neuralgia, neuritis, neuropathy, neurosis, panic attacks, paresis, personality disorder, somnambulism, suicide attempts, tetany, yawning.

Gastrointestinal system: Frequent: diarrhea, dyspepsia, hiccup. Infrequent: anorexia, constipation, dysphagia, flatulence, gastroenteritis. Rare: enteritis, eructation, esophagospasm, gastritis, hemorrhoids, intestinal obstruction, rectal hemorrhage, tooth caries.

Hematologic and lymphatic system: Rare: anemia, hyperhemoglobinemia, leukopenia, lymphadenopathy, macrocytic anemia, purpura, thrombosis.

Immunologic system: Infrequent: infection. Rare: abscess herpes simplex herpes zoster, otitis externa, otitis media.

Liver and biliary system: Infrequent: abnormal hepatic function, increased SGPT. Rare: bilirubinemia, increased SGOT.

Metabolic and nutritional: Infrequent: hyperglycemia, thirst. Rare: gout, hypercholesteremia, hyperlipidemia, increased alkaline phosphatase, increased BUN, periorbital edema.

Musculoskeletal system: Infrequent: arthritis. Rare: arthrosis, muscle weakness, sciatica, tendinitis.

Reproductive system: Infrequent: menstrual disorder, vaginitis. Rare: breast fibroadenosis, breast neoplasm, breast pain.

Respiratory system: Frequent: sinusitis. Infrequent: bronchitis, coughing, dyspnea. Rare: bronchospasm, epistaxis, hypoxia, laryngitis, pneumonia.

Skin and appendages: Infrequent: pruritus. Rare: acne, bullous eruption, dermatitis, furunculosis, injection-site inflammation, photosensitivity reaction, urticaria.

Special senses: Frequent: diplopia, vision abnormal. Infrequent: eye irritation, eye pain, scleritis, taste perversion, tinnitus. Rare: conjunctivitis, corneal ulceration, lacrimation abnormal, parosmia, photopsia.

Urogenital system: Frequent: urinary tract infection. Infrequent: cystitis, urinary incontinence. Rare: acute renal failure, dysuria, micturition frequency, nocturia, polyuria, pyelonephritis, renal pain, urinary retention.



REPORTS OF SUSPECTED AMBIEN CR SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Ambien CR. The information is not vetted and should not be considered as verified clinical evidence.

Possible Ambien CR side effects / adverse reactions in 44 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-14

Patient: 44 year old male weighing 73.0 kg (160.6 pounds)

Reactions: Suicide Attempt, Multiple Drug Overdose

Adverse event resulted in: hospitalization

Suspect drug(s):
Lexapro
    Dosage: oral ; oral
    Administration route: Oral
    Indication: Depression
    Start date: 2011-01-01
    End date: 2011-01-01

Ambien CR
    Dosage: 12.5 mg (12.5 mg,1 in 1 d),oral ; oral
    Administration route: Oral
    Indication: Insomnia
    Start date: 2010-12-01

Ambien CR
    Dosage: 12.5 mg (12.5 mg,1 in 1 d),oral ; oral
    Administration route: Oral
    Indication: Insomnia
    Start date: 2011-01-01
    End date: 2011-01-01

Lunesta
    Dosage: 2 mg (2 mg,1 in 1 d),oral ; oral
    Administration route: Oral
    Indication: Insomnia
    Start date: 2010-10-01
    End date: 2010-12-01

Lunesta
    Dosage: 2 mg (2 mg,1 in 1 d),oral ; oral
    Administration route: Oral
    Indication: Insomnia
    Start date: 2011-01-01
    End date: 2011-01-01

Xanax
    Dosage: oral ; oral
    Administration route: Oral
    Indication: Depression
    Start date: 2011-01-01
    End date: 2011-01-01



Possible Ambien CR side effects / adverse reactions in 62 year old male

Reported by a consumer/non-health professional from United States on 2011-12-12

Patient: 62 year old male

Reactions: Glaucoma, Neck Pain, Coronary Artery Occlusion, Skin Warm, Skin Swelling, Back Pain, Pain in Extremity, Wound Infection Fungal, Pain of Skin, Musculoskeletal Pain, Hyperaesthesia, Testicular Pain, Memory Impairment, Arthritis, DRY Eye, Hydrocele, Testicular Cyst

Adverse event resulted in: hospitalization

Suspect drug(s):
Ambien CR

Ambien CR
    Administration route: Oral
    Start date: 2009-01-01



Possible Ambien CR side effects / adverse reactions in 62 year old male

Reported by a consumer/non-health professional from United States on 2011-12-22

Patient: 62 year old male

Reactions: Glaucoma, Neck Pain, Coronary Artery Occlusion, Skin Swelling, Skin Warm, Back Pain, Pain in Extremity, Pain of Skin, Wound Infection Fungal, Musculoskeletal Pain, Hyperaesthesia, Testicular Pain, Memory Impairment, DRY Eye, Arthritis, Testicular Cyst, Hydrocele

Adverse event resulted in: hospitalization

Suspect drug(s):
Ambien CR

Sertraline Hydrochloride

Ambien CR
    Administration route: Oral
    Start date: 2009-01-01



See index of all Ambien CR side effect reports >>

Drug label data at the top of this Page last updated: 2009-10-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015